Skip to main content
Top
Published in: Current Diabetes Reports 12/2019

01-12-2019 | Insulins | Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (B Conway and H Keenan, Section Editors)

Natural Alternative Sweeteners and Diabetes Management

Authors: Emily Mejia, Michelle Pearlman

Published in: Current Diabetes Reports | Issue 12/2019

Login to get access

Abstract

Purpose of Review

The goal of this review is to discuss the data on natural alternative sweeteners and their effects on glucose homeostasis and other metabolic parameters within the past five years. We sought to answer whether common natural alternative sweeteners have a positive or negative effect on glucose control in both human and animal models, and whether the data supports their widespread use as a tool to help reduce the prevalence of diabetes and associated comorbid conditions.

Recent Findings

Recent studies suggest that natural alternative sweeteners may reduce hyperglycemia, improve lipid metabolism, and have antioxidant effects particularly in those that have baseline diabetes.

Summary

Diabetes and metabolic syndrome have become a global healthcare crisis and the sugar overconsumption plays a major role. The use of artificial sweeteners has become more prevalent to improve insulin resistance in those with diabetes, obesity, and metabolic syndrome, although the evidence does not support this result. There are however some promising data to suggest that natural alternative sweeteners may be a better alternative to sugar and artificial sweeteners.
Literature
4.
go back to reference Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes care. 2014;37(Supplement 1):S120–S43.CrossRef Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes care. 2014;37(Supplement 1):S120–S43.CrossRef
6.
go back to reference Organization WH. Global report on diabetes. 2016. 2017. Organization WH. Global report on diabetes. 2016. 2017.
7.
go back to reference Bender C, Graziano S, Zimmermann BF. Study of Stevia rebaudiana Bertoni antioxidant activities and cellular properties. Int J Food Sci Nutr. 2015;66(5):553–8.CrossRef Bender C, Graziano S, Zimmermann BF. Study of Stevia rebaudiana Bertoni antioxidant activities and cellular properties. Int J Food Sci Nutr. 2015;66(5):553–8.CrossRef
10.
go back to reference Tey S, Salleh N, Henry J, Forde C. Effects of aspartame-, monk fruit-, stevia-and sucrose-sweetened beverages on postprandial glucose, insulin and energy intake. Int J Obes. 2017;41(3):450.CrossRef Tey S, Salleh N, Henry J, Forde C. Effects of aspartame-, monk fruit-, stevia-and sucrose-sweetened beverages on postprandial glucose, insulin and energy intake. Int J Obes. 2017;41(3):450.CrossRef
11.
go back to reference Ritu M, Nandini J. Nutritional composition of Stevia rebaudiana, a sweet herb, and its hypoglycaemic and hypolipidaemic effect on patients with non-insulin dependent diabetes mellitus. J Sci Food Agric. 2016;96(12):4231–4.CrossRef Ritu M, Nandini J. Nutritional composition of Stevia rebaudiana, a sweet herb, and its hypoglycaemic and hypolipidaemic effect on patients with non-insulin dependent diabetes mellitus. J Sci Food Agric. 2016;96(12):4231–4.CrossRef
12.
go back to reference Onakpoya IJ, Heneghan CJ. Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: a systematic review and meta-analysis of randomised clinical trials. Eur J Prev Cardiol. 2015;22(12):1575–87.CrossRef Onakpoya IJ, Heneghan CJ. Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: a systematic review and meta-analysis of randomised clinical trials. Eur J Prev Cardiol. 2015;22(12):1575–87.CrossRef
14.
go back to reference Elnaga NA, Massoud MI, Yousef M, Mohamed HH. Effect of stevia sweetener consumption as non-caloric sweetening on body weight gain and biochemical’s parameters in overweight female rats. Annals of Agricultural Sciences. 2016;61(1):155–63.CrossRef Elnaga NA, Massoud MI, Yousef M, Mohamed HH. Effect of stevia sweetener consumption as non-caloric sweetening on body weight gain and biochemical’s parameters in overweight female rats. Annals of Agricultural Sciences. 2016;61(1):155–63.CrossRef
15.
go back to reference Assaei R, Mokarram P, Dastghaib S, Darbandi S, Darbandi M, Zal F, et al. Hypoglycemic effect of aquatic extract of Stevia in pancreas of diabetic rats: PPARγ-dependent regulation or antioxidant potential. Avicenna journal of medical biotechnology. 2016;8(2):65.PubMedPubMedCentral Assaei R, Mokarram P, Dastghaib S, Darbandi S, Darbandi M, Zal F, et al. Hypoglycemic effect of aquatic extract of Stevia in pancreas of diabetic rats: PPARγ-dependent regulation or antioxidant potential. Avicenna journal of medical biotechnology. 2016;8(2):65.PubMedPubMedCentral
17.
go back to reference • Akbarzadeh S, Eskandari F, Tangestani H, Bagherinejad ST, Bargahi A, Bazzi P et al. The effect of Stevia rebaudiana on serum omentin and visfatin level in STZ-induced diabetic rats. Journal of dietary supplements. 2015;12(1):11-22. Proposed molecular mechanism for stevia’s insulin-mimetic properties. • Akbarzadeh S, Eskandari F, Tangestani H, Bagherinejad ST, Bargahi A, Bazzi P et al. The effect of Stevia rebaudiana on serum omentin and visfatin level in STZ-induced diabetic rats. Journal of dietary supplements. 2015;12(1):11-22. Proposed molecular mechanism for stevia’s insulin-mimetic properties.
18.
go back to reference Mooradian AD, Smith M, Tokuda M. The role of artificial and natural sweeteners in reducing the consumption of table sugar: a narrative review. Clinical nutrition eSPen. 2017;18:1–8.CrossRef Mooradian AD, Smith M, Tokuda M. The role of artificial and natural sweeteners in reducing the consumption of table sugar: a narrative review. Clinical nutrition eSPen. 2017;18:1–8.CrossRef
20.
go back to reference Han Y, Kwon E-Y, Yu M, Lee S, Kim H-J, Kim S-B, et al. A preliminary study for evaluating the dose-dependent effect of d-allulose for fat mass reduction in adult humans: a randomized, double-blind. Placebo-Controlled Trial Nutrients. 2018;10(2):160. https://doi.org/10.3390/nu10020160.CrossRef Han Y, Kwon E-Y, Yu M, Lee S, Kim H-J, Kim S-B, et al. A preliminary study for evaluating the dose-dependent effect of d-allulose for fat mass reduction in adult humans: a randomized, double-blind. Placebo-Controlled Trial Nutrients. 2018;10(2):160. https://​doi.​org/​10.​3390/​nu10020160.CrossRef
22.
go back to reference • Ensor M, Williams J, Smith R, Banfield A, Lodder RA. Effects of three low-doses of D-tagatose on glycemic control over six months in subjects with mild type 2 diabetes mellitus under control with diet and exercise. Journal of endocrinology, diabetes & obesity. 2014;2(4):1057. Identifies minimum dosage required to see positive effects on blood glucose after six months of treatment. • Ensor M, Williams J, Smith R, Banfield A, Lodder RA. Effects of three low-doses of D-tagatose on glycemic control over six months in subjects with mild type 2 diabetes mellitus under control with diet and exercise. Journal of endocrinology, diabetes & obesity. 2014;2(4):1057. Identifies minimum dosage required to see positive effects on blood glucose after six months of treatment.
23.
go back to reference •• Ensor M, Banfield AB, Smith RR, Williams J, Lodder RA. Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of endocrinology, diabetes & obesity. 2015;3(1). Results were reproducible with a longer treatment period with a larger and more diverse participant population. •• Ensor M, Banfield AB, Smith RR, Williams J, Lodder RA. Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of endocrinology, diabetes & obesity. 2015;3(1). Results were reproducible with a longer treatment period with a larger and more diverse participant population.
25.
go back to reference • Shintani T, Yamada T, Hayashi N, Iida T, Nagata Y, Ozaki N et al. Rare sugar syrup containing D-allulose but not high-fructose corn syrup maintains glucose tolerance and insulin sensitivity partly via hepatic glucokinase translocation in Wistar rats. Journal of agricultural and food chemistry. 2017;65(13):2888-94. Evaluates the mechanism of action of rare sugars and suggests that RSS affects glucose metabolism through GK and increased glycogen levels. CrossRef • Shintani T, Yamada T, Hayashi N, Iida T, Nagata Y, Ozaki N et al. Rare sugar syrup containing D-allulose but not high-fructose corn syrup maintains glucose tolerance and insulin sensitivity partly via hepatic glucokinase translocation in Wistar rats. Journal of agricultural and food chemistry. 2017;65(13):2888-94. Evaluates the mechanism of action of rare sugars and suggests that RSS affects glucose metabolism through GK and increased glycogen levels. CrossRef
28.
go back to reference • Nagata Y, Kanasaki A, Tamaru S, Tanaka K. D-psicose, an epimer of D-fructose, favorably alters lipid metabolism in Sprague–Dawley rats. Journal of agricultural and food chemistry. 2015;63(12):3168–76. First study to show that allulose may modulate lipid absorption in the small intestine, explaining its hypolipidemic actions. CrossRef • Nagata Y, Kanasaki A, Tamaru S, Tanaka K. D-psicose, an epimer of D-fructose, favorably alters lipid metabolism in Sprague–Dawley rats. Journal of agricultural and food chemistry. 2015;63(12):3168–76. First study to show that allulose may modulate lipid absorption in the small intestine, explaining its hypolipidemic actions. CrossRef
29.
go back to reference • Hossain A, Yamaguchi F, Hirose K, Matsunaga T, Sui L, Hirata Y et al. Rare sugar D-psicose prevents progression and development of diabetes in T2DM model Otsuka Long-Evans Tokushima Fatty rats. Drug Design, Development and Therapy. 2015:525. doi:https://doi.org/10.2147/dddt.s71289. Long term (greater than 1 year) provides evidence supporting rare sugars’ role in decreasing inflammation. • Hossain A, Yamaguchi F, Hirose K, Matsunaga T, Sui L, Hirata Y et al. Rare sugar D-psicose prevents progression and development of diabetes in T2DM model Otsuka Long-Evans Tokushima Fatty rats. Drug Design, Development and Therapy. 2015:525. doi:https://​doi.​org/​10.​2147/​dddt.​s71289. Long term (greater than 1 year) provides evidence supporting rare sugars’ role in decreasing inflammation.
31.
go back to reference Gray A. Nutritional recommendations for individuals with diabetes. Endotext [Internet]. MDText. com, Inc.; 2015. Gray A. Nutritional recommendations for individuals with diabetes. Endotext [Internet]. MDText. com, Inc.; 2015.
32.
go back to reference Jain T, Grover K. Sweeteners in human nutrition. International Journal of Health Sciences and Research. 2015;5(5):439–51. Jain T, Grover K. Sweeteners in human nutrition. International Journal of Health Sciences and Research. 2015;5(5):439–51.
35.
go back to reference Mohsenpour MA, Kaseb F, Nazemian R, Mozaffari-Khosravi H, Fallahzadeh H, Salehi-Abargouei A. The effect of a new mixture of sugar and sugar-alcohols compared to sucrose and glucose on blood glucose increase and the possible adverse reactions: a phase I double-blind, three-way randomized cross-over clinical trial. Endocrinologia, diabetes y nutricion. 2019. Mohsenpour MA, Kaseb F, Nazemian R, Mozaffari-Khosravi H, Fallahzadeh H, Salehi-Abargouei A. The effect of a new mixture of sugar and sugar-alcohols compared to sucrose and glucose on blood glucose increase and the possible adverse reactions: a phase I double-blind, three-way randomized cross-over clinical trial. Endocrinologia, diabetes y nutricion. 2019.
37.
go back to reference Chukwuma CI, Islam S. Xylitol improves anti-oxidative defense system in serum, liver, heart, kidney and pancreas of normal and type 2 diabetes model of rats. Acta Pol Pharm. 2017;74(3):817–26.PubMed Chukwuma CI, Islam S. Xylitol improves anti-oxidative defense system in serum, liver, heart, kidney and pancreas of normal and type 2 diabetes model of rats. Acta Pol Pharm. 2017;74(3):817–26.PubMed
39.
go back to reference Lee YJ, Jeong J, Kim MO, Nam J-O. The positive effect of luohanguo as sugar substitute on blood glucose and metabolism in streptozotocin-induced diabetic mice. Applied Microscopy. 2016;46(3):140–9.CrossRef Lee YJ, Jeong J, Kim MO, Nam J-O. The positive effect of luohanguo as sugar substitute on blood glucose and metabolism in streptozotocin-induced diabetic mice. Applied Microscopy. 2016;46(3):140–9.CrossRef
40.
go back to reference Gangoso A, Robben DM, Wesley MC, Rodriguez PRR, editors. Comparison of the glycemic response of white sugar and monk fruit sweetener among normoglycemic subjects. 7th International Scholars Conference Proceeding; 2018. Gangoso A, Robben DM, Wesley MC, Rodriguez PRR, editors. Comparison of the glycemic response of white sugar and monk fruit sweetener among normoglycemic subjects. 7th International Scholars Conference Proceeding; 2018.
41.
go back to reference Liu H, Qi X, Yu K, Lu A, Lin K, Zhu J, et al. AMPK activation is involved in hypoglycemic and hypolipidemic activities of mogroside-rich extract from Siraitia grosvenorii (Swingle) fruits on high-fat diet/streptozotocin-induced diabetic mice. Food Funct. 2019. https://doi.org/10.1039/c8fo01486h.CrossRef Liu H, Qi X, Yu K, Lu A, Lin K, Zhu J, et al. AMPK activation is involved in hypoglycemic and hypolipidemic activities of mogroside-rich extract from Siraitia grosvenorii (Swingle) fruits on high-fat diet/streptozotocin-induced diabetic mice. Food Funct. 2019. https://​doi.​org/​10.​1039/​c8fo01486h.CrossRef
Metadata
Title
Natural Alternative Sweeteners and Diabetes Management
Authors
Emily Mejia
Michelle Pearlman
Publication date
01-12-2019
Publisher
Springer US
Keywords
Insulins
Insulins
Published in
Current Diabetes Reports / Issue 12/2019
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-019-1273-8

Other articles of this Issue 12/2019

Current Diabetes Reports 12/2019 Go to the issue

Diabetes and Pregnancy (M-F Hivert and CE Powe, Section Editors)

Diagnostic Strategies for Gestational Diabetes Mellitus: Review of Current Evidence

Therapies and New Technologies in the Treatment of Diabetes (M Pietropaolo, Section Editor)

Bariatric Surgery in the Treatment of Type 2 Diabetes

Health Care Delivery Systems and Implementation in Diabetes (ME McDonnell and AR Sadhu, Section Editors)

Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration

Hospital Management of Diabetes (A Wallia and JJ Seley, Section Editors)

Hospitalization as an Opportunity to Optimize Glycemic Control in Oncology Patients

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.